Presented by Select Science
The availability of fresh human tissue remains an impediment to the study of solid tumor indications. The generation of a highly-annotated™ cryopreserved dissociated tissue biobank provides the opportunity to develop highly focused study cohorts to understand the complex cellular heterogeneity of human tissues. Performing “-omics” analyses on heterogeneous biological tissue samples can, however, lead to biased results, particularly when the target cells are present in relatively low numbers.

Join this webinar to understand how Discovery Life Science’s cell services laboratory processes primary human tissue for downstream analytical evaluation. Sony’s MA900 cell sorter is an integral part of multiple workflows that support both the analyses of cell populations and preparation of specimens for multiple downstream applications. Experimental data showing single cell resolution of protein expression and results using 10x Genomics single cell RNA-seq (scRNA-seq) technology will be discussed.

Learning objectives:

  • Learn how the dissociation and cryopreservation of primary solid tissues can accelerate preclinical pipelines
  • Review the workflow used by Discovery that combines cell sorting, cellular debris clean up, and immunophenotyping of primary human tissue into one step to generate single cell data
  • Discuss the latest approaches such as 10x Genomics and custom cell culture studies used in downstream single cell applications


Who should attend

This webinar will provide insights to researchers who want to learn how to utilize cryopreserved primary solid tissues to accelerate preclinical pipelines. Attendees will learn how to optimize the samples from biobanked tissue using cell sorting to perform single cell transcriptomics studies.



Photo of Dr. Shawn FahlDr Shawn Fahl,
Senior Director, R&D,
Discovery Life Sciences

Dr. Shawn Fahl, is a skilled immunologist working to advance the cellular analytical pipelines and R&D laboratory processes for Discovery Life Sciences, the Biospecimen and Biomarker Specialists™. Dr. Fahl received his PhD in microbiology in 2013 from the University of Virginia, where he studied transcriptional control of B-cell development. He continued his training from 2013 to 2017 as a postdoctoral fellow at Fox Chase Cancer Center, where he focused on genomic regulation during gamma/delta T-cell development. An expert in flow cytometric analyses evaluating lymphocyte biology, Dr. Fahl joined Discovery Life Sciences in June 2017 to advance the analytical workflows for many product lines, including dissociated tissue cells and isolated cell products from apheresis.